UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): December 21, 2007
MEDICAL
DISCOVERIES, INC
(Exact
Name of Registrant as Specified in Charter)
| |
Utah
|
|
| |
(State
of Incorporation)
|
|
|
000-12627
|
|
87-0407858
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
|
6033
W. Century Blvd, Suite 1090, Los
Angeles, California
|
|
90045
|
|
(Address
of Principal Executive Offices)
|
|
(Zip Code)
|
|
(310)
670-7911
|
|
(Registrant’s
Telephone Number, Including Area
Code)
|
| |
|
(Former
Name or Former Address, if Changed
Since Last Report)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
| ITEM
5.02 |
DEPARTURE
OF DIRECTORS AND CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT
OF
CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS
|
On
August
31, 2007, Medical Discoveries, Inc. (the “Company”)
entered into that certain Settlement
and Release Agreement
(the “Agreement”)
with
Judy Robinett, then the Company’s current Chief Executive Officer, regarding the
resignation of Ms. Robinett from all of her positions with the Company. In
order
to assist the Company in its transition from a bio-pharmaceutical company to
an
alternative energy company, under the Agreement Ms. Robinett agreed to continue
to act as the Company’s transitional Chief Executive Officer until the
completion of certain transitional matters and that her resignation would not
become effective until the completion of those matters. On December 21, 2007,
the last of the transitional matters was completed, and, in accordance with
the
Agreement, Ms. Robinett resigned as the Company’s Chief Executive Officer and as
a member of its Board of Directors.
A
copy of
the Agreement was previously filed as an exhibit to the Current Report on Form
8-K filed with the Securities and Exchange Commission on September 17, 2007.
Effective
September 1, 2007, the Company entered into an employment agreement with Richard
Palmer pursuant to which the Company hired Mr. Palmer to serve as its President
and Chief Operating Officer. The employment agreement with Mr. Palmer also
provided that Mr. Palmer would assume the office of Chief Executive Officer
of
the Company following the resignation of Ms. Robinett. Accordingly, effective
December 21, 2007, Mr. Palmer became the Company’s Chief Executive Officer.
A
copy of
Mr. Palmer’s employment agreement was previously filed as an exhibit to the
Current Report on Form 8-K filed with the Securities and Exchange Commission
on
September 17, 2007.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this Report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
MEDICAL
DISCOVERIES, INC. |
|
|
|
| Date:
December 27, 2007 |
By: |
/s/
Richard Palmer |
| |
Richard
Palmer, President and Chief
Executive
Officer
|
| |
|